New oral drug shows promise in fight against deadly lassa fever

NCT ID NCT07419373

Recruiting now Disease control Sponsor: Arisan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 24, 2026 · Updated 15 times

Summary

This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever in hospitalized adults in West Africa. About 135 participants will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin. The goal is to see if the new drug is safe and reduces the virus more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Abubakar Tafawa Balewa University Teaching Hospital
NOT_YET_RECRUITING

Bauchi, Nigeria

Contact Email: •••••@•••••
Arisan Therapeutics
NOT_YET_RECRUITING

Carlsbad, California, 92008, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Federal Medical Centre, Owo
RECRUITING

Owo, Ondo State, Nigeria

Contact Email: •••••@•••••
Irrua Specialist Teaching Hospital
RECRUITING

Irrua, 310115, Nigeria

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LASSA FEVER